Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.
Room3906 Jinmao Tower, 88 Century Boulevard, Shanghai 200121, China
Zhang Ao
Executive Director
Artavazd Arumov Ph.D
Principal
Cyrus Chan
Associate
Nan Chen
Principal
David Chu
Partner
Phil DiGiacomo
Principal
Anna French
Managing Partner
Yuxin Fu
Vice President
Jinda Gao
Principal
Kuantai Yeh
Partner
Robert Headley
Partner
Maykin Ho
Venture Partner
William Hu
Managing Partner
Duane Kuang
Co-Founder and Managing Partner
Nisa Leung
Managing Partner
Dingzheng Li
Vice President
Jing Liu
Vice President
Chang Liu
Associate
Bin Liu
Vice President
Biao Lu
Associate
Shuo Mao
Principal
Will McConnell
Principal
Gary Rieschel
Founder and Managing Partner
James Shen
Venture Partner
Motao Sun
Vice President
Amy Tang
Venture Partner
Yi Tang
Principal
Shiyu Wang
Partner
Rachel Wang
Venture Partner
James Wang
Venture Partner
Jing Wu
Partner
Gillian Xu
RMB funds CFO
Peter (Ming) Yin
Principal, Cleantech
Janet Yu
Partner
Oscar Zhang
Principal
Yafeng Zhou
Associate
Alex Zhou
Partner
Zhiyuan Zhou
Associate
Zhifeng Zhou
Managing Partner
Jing-Shan Hu Ph.D
Venture Partner of Healthcare
Phillip DiGiacomo Ph.D
Principal
Past deals in Growth Stage
Eco Polymer
Series B in 2025
Eco Polymer specializes in research and the production of medical catheters and membrane materials.
Singular Medical
Series C in 2025
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Pulnovo Medical
Series C in 2025
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
Vivatides Therapeutics
Series C in 2025
Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.
Stairway Medical
Series B in 2025
Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.
Auron Therapeutics
Series B in 2025
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.
Baoling Bio
Series B in 2025
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.
Xinzeyuan
Series B in 2025
Xinzeyuan Medical is a manufacturer specializing in precision components and consumables for medical endoscopes. The company focuses on producing minimally invasive surgical instruments and various medical consumables, aimed at enhancing the safety and efficiency of surgical treatments for medical professionals. By delivering high-quality products, Xinzeyuan Medical plays a vital role in supporting healthcare providers and improving patient outcomes.
Umoja Biopharma
Series C in 2025
Umoja Biopharma specializes in innovative immunotherapy aimed at transforming cancer treatment and enhancing patient quality of life. The company focuses on reprogramming T cells within the patient's body to effectively target cancer, including solid tumors and hematological cancers that often have poor responses to conventional therapies. Its proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens tailored to various stages of cancer, enabling medical practitioners to directly and safely attack cancer cells. By harnessing the body's immune response, Umoja Biopharma seeks to improve overall patient outcomes and provide more effective treatment options for those affected by cancer.
Cornerstone Robotics
Series C in 2025
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Leyden Labs
Series B in 2025
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.
AusperBio
Series B in 2024
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.
StepStar
Series B in 2024
The goal of Stepstar is to "Ten Times the Possibility of Everyone" through Intelligent Step. Step Star firmly creates its own super model and actively uses important resources like
Soda Health
Series B in 2024
Soda Health is a healthcare technology company founded in 2021 and based in Chicago, Illinois. The company focuses on addressing health inequities by leveraging social determinants of health. It offers a technology platform designed to assist individuals in identifying, accessing, and funding the resources necessary for a healthy life. By providing a system for administering and reimbursing personalized benefits, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, ultimately promoting better health outcomes.
Bioheng
Series C in 2024
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.
iMile
Series C in 2024
iMile is a logistics and courier services provider operating across the Middle East, specializing in solutions for the e-commerce sector. The company is notable for being the first courier service to effectively address Cash On Delivery (COD) needs, offering a suite of services that includes cash-on-delivery options with tracking, real-time online shipment tracking, and comprehensive customer support available through various channels. iMile also facilitates international transport and maintains overseas warehouses, ensuring efficient last-mile delivery. Its innovative platform enables clients to manage cross-border deliveries seamlessly, enhancing the overall logistics experience.
Duet
Series C in 2024
Duet is a dating application helps you find meaningful relationships based on shared interests and experiences.
XellSmart
Series B in 2024
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
LaNova Medicines
Series C in 2024
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
Tachem
Series B in 2024
Tachem is a biotechnology company that develops, produces, and distributes a range of products derived from the protected amino acid series. These products cater to diverse industries, including medical, healthcare, food, and cosmetics, serving as high-quality chemical raw materials and biotechnical solutions for various applications.
Original Point
Series C in 2024
Original Point focuses on the development of CNC systems with five-axis and multi-axis linkage capabilities.
Hope Medicine
Series B in 2024
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.
Longbio Pharma
Series B in 2024
Longbio Pharma is a biotechnology company focused on developing treatments for patients with complement and allergy diseases, particularly in the autoimmune sector. The company aims to provide affordable and high-quality biomedicines to both domestic and international markets. By leveraging its innovative platform, Longbio Pharma seeks to enhance treatment options for healthcare professionals, ultimately improving patient outcomes in the field of allergy and complement-related illnesses.
Shanghai Mufan Power
Series B in 2024
Mufan Power is a high-tech enterprise specializing in turbomachinery, focused on developing zero-carbon hydrogen power generation technologies. The company manufactures hydrogen gas turbines designed for various applications, including distributed energy systems, data centers, rail transit, marine power, vehicle propulsion, and energy storage peak shaving. Mufan Power also offers technical consultation and engineering services related to gas turbines, steam turbines, and other turbomachinery, having contributed to the design and development of significant national heavy equipment in China.
SPEEDIANCE
Series B in 2024
Speediance focuses on the development of smart self-service gym equipment tailored for at-home strength training. The company offers innovative fitness equipment that integrates an online platform, providing users with training guidance and access to various courses related to strength training. This approach allows individuals to connect with a broader workout community, enhancing their home workout experiences and promoting effective exercise routines.
Pelliot
Series B in 2024
Pelliot is an outdoor sports brand that designs and manufactures high-performance clothing for outdoor enthusiasts. The company specializes in innovative design and research & development, offering a range of products including performance, mountain, classic, and training wear. Pelliot's commitment lies in producing professional-grade outdoor sports products, supporting outdoor lovers with reliable equipment.
TandemAI
Series C in 2024
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.
Outpace Bio
Series B in 2024
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Engitist
Series B in 2024
Engitist is a company based in Suzhou, China, that specializes in the research, manufacture, and sale of semiconductor optical measurement and testing equipment. Founded in 2018, Engitist offers a range of products including microscopic film measurement, optical defect detection, and optical linewidth measurement. The equipment is designed to provide high accuracy and reliability, enabling semiconductor manufacturers to effectively monitor product quality and enhance the sophistication of their semiconductor products. Engitist serves a global clientele, delivering high-quality solutions tailored to the needs of the semiconductor industry.
LaNova Medicines
Series C in 2024
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
Alpha Biopharma
Series B in 2024
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.
Novamab
Series B in 2024
Novamab is engaged in the research and development of innovative nanobody pharmaceuticals aimed at improving treatment options in the pharmaceutical industry. With a team experienced in nanobody research, the company has developed multiple specialized platforms, including an inhaled macromolecular drug platform, an albumin nanobody long-acting platform, and a nanobody double-antibody platform. These innovations leverage the unique advantages of nanobodies to create novel drug delivery methods, such as sprays and eye drops, addressing significant challenges in the management of chronic diseases. Novamab's research focuses on critical medical areas, including tumors, autoimmune disorders, and cardiovascular diseases, ultimately enabling healthcare professionals to enhance patient outcomes.
Dezhen Technology
Series C in 2024
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.
Yidao Biotechnology
Series C in 2024
Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.
CureGenetics
Series B in 2024
CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.
Zhipu AI
Series B in 2024
Zhipu AI is a data company focused on developing an AI-based large model platform that offers API services tailored to various customer needs. The company provides a range of smart application products, including the scientific and technological information analysis engine "AMiner" and AI cognitive engines such as CodeGeeX and CogView. These tools are designed to help users automate and optimize digital tasks, thereby reducing the required manual labor. Zhipu AI's advanced applications are built on its General Language Model (GLM) series, capable of handling tasks in both Chinese and English, making its offerings versatile and applicable across different linguistic contexts.
DH-Robotics
Series C in 2024
DH Robotics Technology Co., Ltd., founded in 2016 and based in China, specializes in the research and development of robotic hands and industrial robots. The company focuses on creating electric gripping jaws intended to enhance intelligent manufacturing processes. Its products are designed to be stable, secure, and easily integrated, catering to the needs of advanced manufacturing and lean production. By developing cost-effective solutions, DH Robotics aims to support flexible and intelligent demands within the manufacturing sector.
Alamar Biosciences
Series C in 2024
Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.
Hope Medicine
Series B in 2024
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.
Ruining Bio
Series B in 2024
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.
DeBank
Series B in 2024
DeBank is a cryptocurrency wallet designed to facilitate access to decentralized finance (DeFi) services, enabling users to manage and track their DeFi investments effectively. The platform supports over 800 DeFi protocols across more than 15 blockchains, including Ethereum and Binance Smart Chain. Users can monitor their asset portfolios, compare interest rates, and analyze risks associated with their investments. DeBank also offers features for token swapping and discovering new investment opportunities through detailed real-time data, allowing users to gain insights into their financial activities and optimize their returns in the DeFi space.
Leapstack
Series C in 2023
Leapstack is an insurance technology company based in Shanghai, with additional offices in Beijing and Nanjing. Founded in February 2016, it focuses on developing big data artificial intelligence solutions tailored for commercial insurance companies and social security management agencies. The company's platform enhances the insurance claims process by offering services such as risk control monitoring, post-medical reimbursement, anti-fraud measures, and compliance identification. By addressing inefficiencies in the industry, Leapstack aims to improve operational effectiveness and provide comprehensive data analysis and management tools for its clients.
ABUP
Series B in 2023
ABUP specializes in over-the-air (OTA) solutions for the automotive and Internet of Things (IoT) sectors. The company offers a range of products and services, including firmware upgrades, software upgrades, and cloud diagnosis for automobiles, as well as IoT upgrade solutions. By leveraging artificial intelligence and big data, ABUP enables its customers to keep their products current, ensuring users benefit from a tailored experience and ongoing innovation. Their technology supports original equipment manufacturers by providing comprehensive OTA system solutions that enhance product management and upgrades in the rapidly evolving IoT landscape.
Saints & Sages
Series B in 2023
Saints & Sages Medical specializes in the production and sale of minimally invasive surgical medical devices. The company offers a range of energy device products utilized across various medical fields, including hepatobiliary surgery, gynecology, urology, thoracic surgery, thyroid and breast surgery, and gastrointestinal surgery. By closely monitoring clinical needs, Saints & Sages is committed to developing innovative surgical devices that enhance the accuracy and efficiency of procedures. The company is supported by a dedicated research and development team with extensive experience in clinical transformation, allowing it to continually advance its offerings to better serve patients worldwide.
Solo Music
Series B in 2023
Solo Music is an AI-based music education platform that provides online education services for several musical instruments.
Zhipu AI
Series B in 2023
Zhipu AI is a data company focused on developing an AI-based large model platform that offers API services tailored to various customer needs. The company provides a range of smart application products, including the scientific and technological information analysis engine "AMiner" and AI cognitive engines such as CodeGeeX and CogView. These tools are designed to help users automate and optimize digital tasks, thereby reducing the required manual labor. Zhipu AI's advanced applications are built on its General Language Model (GLM) series, capable of handling tasks in both Chinese and English, making its offerings versatile and applicable across different linguistic contexts.
Cornerstone Robotics
Series B in 2023
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
CuroVax
Series B in 2023
CuroVax, established in 2011 and headquartered in Changzhou City, China, specializes in vaccine development and production. It offers a range of vaccines, including a Freeze-Dried rabies vaccine for human use and an Influenza virus split vaccine, along with related logistics services. The company employs a dual approach of independent development and collaborative research, supported by multiple technology platforms such as large-scale mammalian cell culture and antigen purification, vaccine testing, and mRNA vaccine development. CuroVax aims to provide safe and efficient products, contributing to the improvement of global health.
Abdera Therapeutics
Series B in 2023
Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.
1 Yong Cloud
Series B in 2023
1 Yong Cloud is a Beijing-based company founded in 2017 that specializes in developing a tumor diagnosis and treatment standardization platform. This platform is designed to assist physicians in creating personalized diagnosis and treatment plans for patients with tumor diseases. By collecting and translating medical data, 1 Yong Cloud aims to enhance the quality and consistency of medical care while rationalizing treatment expenses. The company's comprehensive data and system services support healthcare professionals in improving the overall effectiveness of tumor diagnosis and treatment.
Allorion Therapeutics
Series B in 2023
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.
Jiangsu Jing Chuang Advanced Electronic Technology focuses on the research and development of equipment for the semiconductor manufacturing sector. The company specializes in high-precision grinding machines and offers a range of products, including automatic laser saws, dicing saws, and wafer cleaning equipment. By providing comprehensive solutions for semiconductor material dicing applications, Jing Chuang Advanced aims to support the growing demands of the semiconductor industry.
Vongi
Series B in 2023
Vongi offers medical solution design, product design and RandD, pilot test transformation, clinical research, registration services, and commercial operations for companies that need digital therapy, real-world research, and digital therapy CDMO and process services. For inquiries, their email address, telephone number, and physical address are available on their website.
OriCell Therapeutics
Series B in 2023
OriCell Therapeutics is a biopharmaceutical company dedicated to developing innovative, effective, and affordable tumor immunotherapy treatments. It focuses on unmet clinical needs, with a pipeline targeting various cancers including liver, myeloma, ovarian, gastric, cervical, and non-small cell lung cancers.
SinoUnited Health
Series C in 2023
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
Hochuen Medical
Series B in 2023
Hochuen Medical USA Corp. is a manufacturer of medical devices and consumables, specializing in In Vitro Diagnostics (IVD), wearable medical technology, and microfluidic devices. Established in 2015 by Dr. Robin Liu and Eric Zeng, the company operates as an OEM/ODM manufacturer, providing services that range from product design and development to mass production. Hochuen Medical's product offerings include essential healthcare items such as COVID-19 testing kits, microfluidic biochips, and various medical disposables. The company is recognized for its commitment to quality, holding FDA registration and ISO certifications, and emphasizes research and development to offer innovative solutions for the healthcare sector. With a founding management team that possesses extensive experience in manufacturing and development, Hochuen Medical aims to address the evolving needs of medical professionals and patients through its diverse product portfolio.
Tingsheng Technology
Series B in 2023
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.
Yike Polymers
Series B in 2023
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Singular Medical
Series B in 2023
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Insyce
Series B in 2023
Insyce creates equipment and apparatus for science. Its business strives to provide tools and technology for bio labs that monitor the environment to deliver accurate data and speedy chemical analysis while keeping lab costs down for their clients. It is dedicated to providing upper biological separation equipment and chemical analysis tools for global clients, cutting down on client operating expenses, and adding value for clients.
Fitlens
Series B in 2022
Fitlens is a company that provides ophthalmic medical treatment. They specialize in the design and manufacture of high-end, complicated optical contact lenses as well as the design and manufacture of high-end intraocular lens optical molds.
Core Medical
Series B in 2022
Core Medical (Beijing) Co., Ltd. is a contract research organization (CRO) founded in 2013 and based in Beijing, China. The company specializes in clinical professional services focused on new technologies and innovative products within the cardiovascular sector. Core Medical offers a range of services, including animal testing, type testing, First-in-Man (FIM) studies, human studies, and statistics and data management for clinical research. By providing these services, Core Medical helps companies in the cardiovascular field evaluate and validate their products, facilitating advancements in medical technology.
Focallure
Series B in 2022
Focallure is a cosmetic company headquartered in Guangzhou, China, specializing in the development and manufacture of beauty products, particularly base makeup and cosmetics. The company leverages big data analysis to enhance its operations by analyzing consumer product preferences and social content trends. This data-driven approach allows Focallure to create innovative products that aim to provide users with a fresh makeup experience.
Prismlab China
Series C in 2022
Prismlab China Ltd. is a high-tech enterprise established in 2005, specializing in the development, production, and sales of high-speed light-curing 3D printers. The company integrates optical, mechanical, electrical technology, and computer software and hardware, along with photopolymer materials, to produce advanced rapid prototyping machines based on SLA technology. With a global presence, its products are distributed across over 50 countries and regions, earning recognition and acclaim from users worldwide for their performance and innovation.
iMile
Series B in 2022
iMile is a logistics and courier services provider operating across the Middle East, specializing in solutions for the e-commerce sector. The company is notable for being the first courier service to effectively address Cash On Delivery (COD) needs, offering a suite of services that includes cash-on-delivery options with tracking, real-time online shipment tracking, and comprehensive customer support available through various channels. iMile also facilitates international transport and maintains overseas warehouses, ensuring efficient last-mile delivery. Its innovative platform enables clients to manage cross-border deliveries seamlessly, enhancing the overall logistics experience.
Fushoukang
Series C in 2022
Shanghai Fushoukang Rehabilitative Home Nursing Services specializes in in-home rehabilitation and nursing care for the elderly, as well as individuals who are weak, sick, or disabled. Founded in 2011 and headquartered in Shanghai, the company offers a range of services including home care, community care, nursing care, and bathing assistance. By focusing on the needs of vulnerable populations, Fushoukang aims to enhance the quality of life for its clients through personalized care in the comfort of their own homes.
Scroll.io
Series B in 2022
Scroll.io provides a native zkEVM scaling solution for Ethereum. The company upholds the Ethereum network's high-security features while offering users nearly instantaneous, inexpensive transactions.
Norm Medtech
Series B in 2022
Norm Medtech focuses on developing interventional medical devices. Norm Medtech is headquartered in Zhejiang, China.
OriCell Therapeutics
Series B in 2022
OriCell Therapeutics is a biopharmaceutical company dedicated to developing innovative, effective, and affordable tumor immunotherapy treatments. It focuses on unmet clinical needs, with a pipeline targeting various cancers including liver, myeloma, ovarian, gastric, cervical, and non-small cell lung cancers.
GYENNO Technologies
Series B in 2022
GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.
OriginCell
Series B in 2022
OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments. OriginCell was founded in 2014 and is headquartered in Shanghai, China.
Biren Technology
Series B in 2022
Biren Technology is a high-tech startup specializing in the design and development of intelligent processors tailored for GPU and DSA computation architectures. The company focuses on creating integrated software and hardware platforms that support intelligent computing applications, including cloud computing, artificial intelligence training, graphics rendering, and high-performance general-purpose computing. With a dedicated team of industry experts and elite engineers, Biren Technology aims to deliver versatile computing solutions that blend general computing capabilities with specific applications. Its research division is committed to advancing key technologies in intelligent computing systems, emphasizing new architectures and advanced compilation techniques, thereby facilitating technological breakthroughs in various high-tech sectors.
Tasogare
Series C in 2022
Tasogare Coffee is a premium coffee brand based in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, catering to a wide customer base that values high-quality coffee. Tasogare Coffee is committed to delivering exceptional coffee experiences, emphasizing quality in its offerings.
Chatail
Series B in 2022
Chatail is a company that specializes in live broadcast sales solutions tailored for private domains. It provides a comprehensive platform that allows businesses to effectively leverage live video for sales purposes. Key features of Chatail's offerings include capabilities for cross-store linking and tools for enhancing enterprise collaboration without the need for live broadcasting. The company develops software that assists brands in initiating live video commerce, empowering sales associates and call center representatives to attract customers to physical retail locations while facilitating meaningful interaction and communication.
Qingflow
Series B in 2022
Qingflow is a software-as-a-service platform based in the Minhang District of Shanghai, specializing in business workflow management. The platform allows users to create customized management systems by freely designing and combining various modules. This flexibility enables individuals and organizations to develop personalized business workflows tailored to their specific needs, all without requiring any programming skills. Qingflow's approach empowers users to effectively manage their operations and enhance productivity through a user-friendly interface.
Gaugene
Series B in 2022
Gaugene specializes in providing advanced hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. As a high-tech enterprise, it is backed by experienced professionals from prominent domestic IVD companies who possess expertise in leading-edge technologies. The company’s instruments are unique in China, featuring high-power flow lasers and high-sensitivity multi-color fluorescence detection systems. These innovations enable a wide range of applications, including hematology diagnosis, clinical diagnosis, and life science research. Gaugene's solutions support clinical diagnostics and flow cytometry technology, facilitating single-cell research, protein screening, and the discovery of new clinical indicators.
RiboX Therapeutics
Series B in 2022
RiboX Therapeutics is a biotech company that focuses on discovery and development of fully engineered circular RNA therapeutics.
Cubenergy Technology
Series B in 2022
Cubenergy Technology is an energy technology company specializing in energy data operation services and the integration of distributed energy storage systems. The company develops advanced Energy Management Systems that utilize data analysis to optimize the performance of energy storage systems. By focusing on efficient control mechanisms, Cubenergy Technology aims to enhance system efficiency and provide users with effective energy management solutions.
LaNova Medicines
Series B in 2022
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
Boulder Care
Series B in 2022
Boulder Care, Inc. is a telemedicine-based platform focused on treating opioid addiction through a combination of medication and peer support. Founded in 2017 and located in Portland, Oregon, the company provides comprehensive services that include patient support, medication management, and psychosocial services. By leveraging digital health technology, Boulder Care aims to improve access to effective treatment for individuals struggling with opioid use, enhancing the experience for both patients and their care teams. The organization serves a diverse clientele, including patients, providers, and various health organizations, contributing to the advancement of the behavioral health industry.
Point One
Series B in 2022
Point One is a 3D Metaverse user-generated content platform. Using simple no-code tools, users may build personalized 3D interactive content.
BUD
Series B in 2022
BUD, founded in 2019 by former Snap engineers Risa Feng and Shawn Lin, is a Singapore-based company that operates a user-generated open metaverse gaming platform. This platform connects millions of virtual worlds created by a community of approximately 9 million creators. Since its global launch in November 2021, BUD has rapidly gained popularity, ranking among the top 10 social apps in over 38 countries, including regions in North America, Southeast Asia, and South America. The platform allows users to easily customize 3D worlds through a simple drag-and-drop interface, enabling the creation and sharing of interactive experiences that range from social hangouts to competitive games. BUD has evolved into a vibrant digital social hub where users can create, play, and interact with 3D content alongside friends.
Yike Polymers
Series B in 2022
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Ashermed
Series B in 2022
Ashermed is a provider of contract research organization (CRO) services tailored for medical companies. The company emphasizes the integration of advanced technologies, including Internet technology, big data, and artificial intelligence, into its offerings. By doing so, Ashermed aims to help medical companies shorten the drug development cycle, enhance the quality of clinical data, and lower research and development costs. Their services encompass CRO, site management organization (SMO), patient recruitment, and digital platform support, positioning them as a comprehensive partner in the medical research industry.
Onechip Bioelectronics
Series B in 2022
Wanzhong Yixin Biotechnology is a developer of semiconductor integrated circuit biosensor chips and other related devices. The company's biosensor chip products are used in emerging fields such as genetic testing, water quality monitoring, and environmental protection IoT monitoring.
Belief Biomed
Series C in 2022
Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.
Curie.Bio
Series B in 2022
Curie.Bio, founded in 2022 and based in Boston, Massachusetts, is a venture capital firm that specializes in seed-stage investments. The firm focuses on early-stage therapeutics companies, aiming to support innovative solutions in the life sciences sector. As a Registered Investment Adviser, Curie.Bio is dedicated to fostering growth and development in the biotechnology field by partnering with founders and providing the necessary resources to help advance their ventures.
Vistel
Series B in 2022
Vistel is a technology company founded in 2016 by Sun Yuhui and Ding Dayong, specializing in the application of artificial intelligence in the medical field. The firm focuses on developing AI-driven ophthalmic medical imaging technology designed to enhance the diagnosis of eye diseases. By utilizing advanced diagnostic systems that incorporate computer vision processing and image annotation, Vistel aims to provide medical practitioners with innovative tools for the digital analysis and management of patients' eye conditions.
MeetFuture
Series B in 2022
MeetFuture China is a technology-focused company that specializes in automated transmission systems for the pan-semiconductor industry. Since its establishment in 2016, it has been providing innovative automation solutions to prominent companies in the semiconductor sector. By leveraging control theory, computer science, and advanced information technology, MeetFuture enables industrial detection, control, optimization, dispatch, and management. These capabilities allow clients to significantly reduce operational costs and effectively manage production parameters, contributing to overall industrial upgrading and development through independent and controllable core technologies.
MediLink Therapeutics
Series B in 2022
MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.
HashQuark
Series B in 2022
HashQuark is a provider of staking and blockchain infrastructure services, specializing in the Proof of Stake (PoS) and Delegated Proof of Stake (DPoS) ecosystems. Founded in 2018 and based in Grand Cayman, the company offers a range of services including staking for institutions, individuals, and market professionals, as well as a Staking Cloud that enables token holders to securely store their tokens and earn staking rewards. HashQuark supports all mainstream PoS blockchains and has completed global server deployment, ensuring secure and stable operations for its clients. The company's focus is on providing efficient node management and fostering investment opportunities for both individual and institutional investors within the blockchain space.
Zhipu AI
Series B in 2022
Zhipu AI is a data company focused on developing an AI-based large model platform that offers API services tailored to various customer needs. The company provides a range of smart application products, including the scientific and technological information analysis engine "AMiner" and AI cognitive engines such as CodeGeeX and CogView. These tools are designed to help users automate and optimize digital tasks, thereby reducing the required manual labor. Zhipu AI's advanced applications are built on its General Language Model (GLM) series, capable of handling tasks in both Chinese and English, making its offerings versatile and applicable across different linguistic contexts.
Deep View Technology
Series B in 2022
Deep View Technology specializes in motion capture and the development of augmented reality (AR) and virtual reality (VR) applications. The company focuses on research and development related to three-dimensional computer vision algorithms. Utilizing wearable devices, Deep View Technology's services enable the identification of body part gestures, allowing clients to capture human postures in real time. This innovative approach enhances interactive experiences in virtual environments.
Eigencomm
Series C in 2022
EigenCOMM Ltd. is a Shanghai-based company established in 2017, specializing in the research, development, and sales of cellular network internet chips. The firm focuses on providing complete solutions for Internet of Things (IoT) ecosystems, particularly in the realm of smart home appliances. EigenCOMM's product line includes standard NB-IoT terminal chips, which ensure comprehensive coverage of cellular data connections and extended standby times, positioning the company as a key player in the IoT market.
Zhenge Biotech
Series C in 2022
Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.
CureGenetics
Series B in 2022
CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.
Korro Bio
Series B in 2022
Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.
Yesmro
Series C in 2022
Yesmro, also known as Yimai Gongpin, is a retail company focused on supplying automation parts and industrial supplies to small and medium-sized enterprises. The company offers an extensive range of products, including electrical accessories, wires and cables, and industrial control components, catering specifically to the needs of businesses involved in technological development. By leveraging technology and data-driven approaches, Yesmro aims to deliver affordable and convenient solutions, enabling small enterprises to easily access the industrial products they require for their operations. The company's commitment to providing long-tail services ensures that even niche market needs are met efficiently and cost-effectively.
Tungee
Series B in 2021
Tungee, established in 2016, is a provider of intelligent sales solutions for business-to-business enterprises. By utilizing big data and artificial intelligence technologies, including natural language processing and machine learning, Tungee offers a comprehensive platform that facilitates lead mining, business opportunity engagement, customer relationship management, and order analysis. This platform is designed to help enterprises efficiently identify, contact, and manage customers, thereby reducing customer acquisition costs and enhancing overall sales performance. Tungee has positioned itself as a leader in the Chinese intelligent sales sector, serving over 3,000 enterprise clients, including notable companies such as Alibaba and China Mobile. Through its innovative approach, Tungee addresses the challenges faced by businesses in sales forecasting and customer management.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.